Interested in what biotechs might soon bag an important new drug approval? Then the Motley Fool has a treat for you today.
Below, three of our contributors share their picks for biotechs on the cusp of a make-or-break FDA decision. The upside of a green light is huge considering how much the odds are stacked against an investigational compound making it all the way to approval.
It takes about 12 years for an experimental drug to travel from the laboratory to your medicine cabinet, and the chances it will make it are a meager one in 5,000. According to Forbes, the overall cost of creating a new drug averages $5 billion. Of course, that takes into account all the failures; companies don't spend that on each drug.
The good news is that about 80% of drugs that made it through the gauntlet of clinical testing to Phase III gain FDA approval. So, when a drug gets close to receiving a regulatory decision, investors should be on high alert.
Brian Feroldi: One upcoming FDA decision that I'm especially excited to hear about is for ACADIA Pharmaceuticals' (ACAD -0.85%) Nuplazid, which was submitted last last year as a potential treatment for psychosis associated with Parkinson's disease, or PDP.
The National Parkinson Foundation estimates that roughly 400,000 Americans suffer from PDP, which can cause hallucinations and delusions and places a huge burden on caregivers. In phase 3 trials, Nuplazid was shown to lower the impact that PDP had on patients' lives when compared to placebo, and it also helped improved patients' sleep cycles. Nuplazid helped to reduce the burden placed on caregivers, and the results were seen regardless of the patient's age, sex, or race.
With no other approved drugs on the market to treat PDP, the FDA granted Nuplazid with breakthrough therapy designation and has given it a priority review. The target PDUFA decision date is May 1, 2016 .
This date should be exciting for investors, as well, as peak sales for Nuplazid are currently running around $2 billion. That number could grow considerably in the future, too, since Nuplazid is also being studied as a treatment for Alzheimer's Disease Psychosis and Schizophrenia. If Nuplazid gets the green light on May 1st, then it bodes well for the drug's chances with future conditions. I, for one, am excited to see what will happen.
Sean Williams: The PDUFA decision I'm most looking forward to is Intercept Pharmaceuticals' (ICPT 2.81%) obeticholic acid as a treatment for primary biliary cirrhosis, or PBC, an autoimmune disease that causes bile acids to build up and destroy the liver.
Originally, obeticholic acid, also known as OCA, was slated to be approved (or given a complete response letter detailing what would need to be corrected for approval) in February. However, additional data requests from the Food and Drug Administration wound up pushing the PDUFA date back three months, to May 29, 2016. The FDA also set up a panel review for April 7, 2016.
Even though Intercept was clear that the extension was merely a formality of the FDA asking for more data, it's unnerving to investors considering the potential safety concerns surrounding OCA following the midstage FLINT study for nonalcoholic steatohepatitis, or NASH. Following FLINT, some OCA patients exhibited a rise in LDL-cholesterol (the bad kind) and had other adverse reactions. The delay in OCA's PDUFA decision may have only exacerbated these worries among shareholders.
On the flip side, OCA was wildly successful in treating PBC. As noted in the late-stage POISE trial, 47% and 46% of patients in the 10 mg OCA and 5-10 mg OCA cohorts met the primary endpoint, respectively, whereas just 10% of patients in the placebo cohort met the primary endpoint. The adverse events noted were also similar between OCA and the placebo.
This first approval could be a big one for OCA and Intercept because it would presumably give OCA a clearer path to approval in NASH if late-stage study data proves encouraging. NASH could be a multi-billion indication for Intercept's OCA; this is the reason why the May 29 PDUFA date is so exciting in my book.
Wall Street lost confidence in Clovis' management last November, when the FDA delayed review of its fast-tracked drug rociletinib.The stock promptly crashed 70% and has gone nowhere since. Why?
While the FDA ended up pushing review back only three months (until June 28, 2016), that gave AstraZeneca's competing lung cancer treatment a chance to leap ahead. AstraZeneca's drug Tagrisso will now be an established treatment before rociletinib reaches commercialization. And that is not what the market expected.
So where's the value in Clovis? The market is acting as if rociletinib is dead, but the FDA saw enough in the clinical data to delay, not kill, the review. At this point, it's likely rociletinib will eventually get approved.
And even if something does go wrong -- which is always possible with drug approvals -- Clovis has another highly promising drug, rucaparib, a PARP inhibitor for ovarian cancer in late-stage trials. Rucaparib clocks in with a $1 billion peak sales forecast.
Rociletinib is also under accelerated assessment in the EU, with a decision expected in mid-2016, and it's being tested in tandem with a Roche checkpoint inhibitor to see if it could have a positive add-on effect. Clovis is a high-risk stock, but it's worth remembering that the pendulum swings both ways in biotech. If rociletinib gets the FDA nod, that will do a lot to restore faith in Clovis' management, and this stock could head skyward again.